Latest & greatest articles for statin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on statin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on statin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for statin

181. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. Full Text available with Trip Pro

Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. Reducing levels of low-density lipoprotein cholesterol (LDL-C) with intensive statin therapy reduces progression of coronary atherosclerosis in proportion to achieved LDL-C levels. Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors produce incremental LDL-C lowering in statin-treated patients; however, the effects of these drugs on coronary atherosclerosis have (...) not been evaluated.To determine the effects of PCSK9 inhibition with evolocumab on progression of coronary atherosclerosis in statin-treated patients.The GLAGOV multicenter, double-blind, placebo-controlled, randomized clinical trial (enrollment May 3, 2013, to January 12, 2015) conducted at 197 academic and community hospitals in North America, Europe, South America, Asia, Australia, and South Africa and enrolling 968 patients presenting for coronary angiography.Participants with angiographic coronary

2016 JAMA Controlled trial quality: predicted high

182. Statins for Prevention of Cardiovascular Disease in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force. Full Text available with Trip Pro

Statins for Prevention of Cardiovascular Disease in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force. Cardiovascular disease (CVD), the leading cause of mortality and morbidity in the United States, may be potentially preventable with statin therapy.To systematically review benefits and harms of statins for prevention of CVD to inform the US Preventive Services Task Force.Ovid MEDLINE (from 1946), Cochrane Central Register of Controlled Trials (from 1991 (...) ), and Cochrane Database of Systematic Reviews (from 2005) to June 2016.Randomized clinical trials of statins vs placebo, fixed-dose vs titrated statins, and higher- vs lower-intensity statins in adults without prior cardiovascular events.One investigator abstracted data, a second checked data for accuracy, and 2 investigators independently assessed study quality using predefined criteria. Data were pooled using random-effects meta-analysis.All-cause mortality, CVD-related morbidity or mortality

2016 JAMA

183. Predictors of Cardiovascular Hospitalization in Giant Cell Arteritis: Effect of Statin Exposure. A French Population-based Study (Abstract)

Predictors of Cardiovascular Hospitalization in Giant Cell Arteritis: Effect of Statin Exposure. A French Population-based Study To identify predictors and protectors for cardiovascular hospitalization in a giant cell arteritis (GCA) population-based cohort.Using the French National Health Insurance system, we included patients with incident GCA from the Midi-Pyrenees region, southern France, from January 2005 to December 2008 and randomly selected 6 controls matched by sex and age at calendar (...) 1000 person-years versus 14.9, 4.6, 6.2, and 2.5 events per 1000 person-years among controls, respectively. In patients with GCA, cardiovascular comorbidities at diagnosis (HR 6.2, 2.0-19.2), age over 77 years (HR 5.0, 1.40-17.54), as well as the cumulative defined daily dose of statins (HR 0.993, 0.986-0.999) were independent predictors for subsequent cardiovascular hospitalization. None of the 25 patients with GCA who were taking platelet aggregation inhibitors experienced a cardiovascular

2016 EvidenceUpdates

184. Effect on Fasting Serum Glucose Levels of Adding Ezetimibe to Statins in Patients With Nondiabetic Hypercholesterolemia Full Text available with Trip Pro

Effect on Fasting Serum Glucose Levels of Adding Ezetimibe to Statins in Patients With Nondiabetic Hypercholesterolemia Statin therapy is associated with a slightly increased risk of developing diabetes mellitus and insulin resistance in patients without diabetes. Ezetimibe combined with statins may be considered for high-risk patients who do not achieve optimal low-density lipoprotein cholesterol lowering on statin monotherapy or who are statin intolerant. Changes in fasting serum glucose (FSG (...) ) levels during ezetimibe, ezetimibe/statin, and statin treatments were assessed using data pooled from clinical trials in hypercholesterolemic and heterozygous familial hypercholesterolemic patients, who were or were not receiving statin therapy. Study types included first-line trials in statin-naive/wash-out patients and second-line add-on and uptitration studies in patients on stable statin therapy. Similar analyses of FSG changes were performed separately for each study type in patients who were

2016 EvidenceUpdates

185. Effect of statin treatment on vasospasm-related morbidity and functional outcome in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis Full Text available with Trip Pro

Effect of statin treatment on vasospasm-related morbidity and functional outcome in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis OBJECTIVE The efficacy of statin therapy in treating aneurysmal subarachnoid hemorrhage (SAH) remains controversial. In this meta-analysis, the authors investigated whether statin treatment significantly reduced the incidence of cerebral vasospasm and delayed neurological deficits, promoting a better outcome after aneurysmal (...) SAH. METHODS A literature search of the PubMed, Ovid, and Cochrane Library databases was performed for randomized controlled trials (RCTs) and prospective cohort studies investigating the effect of statin treatment. The end points of cerebral vasospasm, delayed ischemic neurological deficit (DIND), delayed cerebral infarction, mortality, and favorable outcome were statistically analyzed. RESULTS Six RCTs and 2 prospective cohort studies met the eligibility criteria, and a total of 1461 patients

2016 EvidenceUpdates

186. PCSK9 Inhibitors: Who Could Need More than a Statin?

PCSK9 Inhibitors: Who Could Need More than a Statin? PCSK9 Inhibitors: Who Could Need More than a Statin? – Clinical Correlations Search PCSK9 Inhibitors: Who Could Need More than a Statin? October 5, 2016 5 min read By Rhodes Hambrick Peer Reviewed The atherosclerotic cardiovascular disease (ASCVD) risk associated with hyperlipidemia (HLD), readily of the mid-20 th century, has been the target of innumerable attempted pharmacologic interventions ever since. One class of agents, the HMG-CoA (...) reductase inhibitors, or statins, became – and have remained 2 – the gold standard for managing HLD-associated ASCVD risk in the setting of the remarkably favorable findings of multiple studies in the 1990s. 3-5 While other agents, including niacin, fish oil, and fibrates, have been demonstrated to have favorable effects on some combination of LDL, HDL, and triglycerides, only statins have been conclusively proven to be of consistent, predictable benefit in reducing ASCVD-related morbidity and mortality

2016 Clinical Correlations

187. Patient and Partner Feedback Reports to Improve Statin Medication Adherence: A Randomized Control Trial Full Text available with Trip Pro

Patient and Partner Feedback Reports to Improve Statin Medication Adherence: A Randomized Control Trial Simple nudges such as reminders and feedback reports to either a patient or a partner may facilitate improved medication adherence.To test the impact of a pill bottle used to monitor adherence, deliver a daily alarm, and generate weekly medication adherence feedback reports on statin adherence.Three-month, three-arm randomized clinical trial (ClinicalTrials.gov identifier: NCT02480530).One (...) and = 0.001). At 6 months, there was no difference in medication adherence between either of the feedback groups and the control (individual feedback 60 %, partner feedback 52 %, control group 54 %; p = 0.75 and 0.97).Daily alarms combined with individual or partner feedback reports improved statin medication adherence. While neither an individual feedback nor partner feedback strategy created a sustainable medication adherence habit, the intervention itself is relatively easy to implement and low cost.

2016 EvidenceUpdates Controlled trial quality: uncertain

188. Statin withdrawal in people with dementia. Full Text available with Trip Pro

Statin withdrawal in people with dementia. There are approximately 24 million people worldwide with dementia; this is likely to increase to 81 million by 2040. Dementia is a progressive condition, and usually leads to death eight to ten years after first symptoms. End-of-life care should emphasise treatments that optimise quality of life and physicians should minimise unnecessary or non-beneficial interventions. Statins are 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (...) ; they have become the cornerstone of pharmacotherapy for the management of hypercholesterolaemia but their ability to provide benefit is unclear in the last weeks or months of life. Withdrawal of statins may improve quality of life in people with advanced dementia, as they will not be subjected to unnecessary polypharmacy or side effects. However, they may help to prevent further vascular events in people of advanced age who are at high risk of such events.To evaluate the effects of withdrawal

2016 Cochrane

189. Interpretation of the evidence for the efficacy and safety of statin therapy. Full Text available with Trip Pro

Interpretation of the evidence for the efficacy and safety of statin therapy. This Review is intended to help clinicians, patients, and the public make informed decisions about statin therapy for the prevention of heart attacks and strokes. It explains how the evidence that is available from randomised controlled trials yields reliable information about both the efficacy and safety of statin therapy. In addition, it discusses how claims that statins commonly cause adverse effects reflect (...) a failure to recognise the limitations of other sources of evidence about the effects of treatment. Large-scale evidence from randomised trials shows that statin therapy reduces the risk of major vascular events (ie, coronary deaths or myocardial infarctions, strokes, and coronary revascularisation procedures) by about one-quarter for each mmol/L reduction in LDL cholesterol during each year (after the first) that it continues to be taken. The absolute benefits of statin therapy depend

2016 Lancet

190. Statins for aortic valve stenosis. Full Text available with Trip Pro

Statins for aortic valve stenosis. Aortic valve stenosis is the most common type of valvular heart disease in the USA and Europe. Aortic valve stenosis is considered similar to atherosclerotic disease. Some studies have evaluated statins for aortic valve stenosis.To evaluate the effectiveness and safety of statins in aortic valve stenosis.We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, LILACS - IBECS, Web of Science and CINAHL Plus. These databases (...) were searched from their inception to 24 November 2015. We also searched trials in registers for ongoing trials. We used no language restrictions.Randomised controlled clinical trials (RCTs) comparing statins alone or in association with other systemic drugs to reduce cholesterol levels versus placebo or usual care.Primary outcomes were severity of aortic valve stenosis (evaluated by echocardiographic criteria: mean pressure gradient, valve area and aortic jet velocity), freedom from valve

2016 Cochrane

191. A Simple Disease-Guided Approach to Personalize ACC/AHA-Recommended Statin Allocation in Elderly People: The BioImage Study Full Text available with Trip Pro

A Simple Disease-Guided Approach to Personalize ACC/AHA-Recommended Statin Allocation in Elderly People: The BioImage Study The 2013 American College of Cardiology (ACC)/American Heart Association (AHA) guidelines recommend primary prevention with statins for individuals with ≥7.5% 10-year risk for atherosclerotic cardiovascular disease (ASCVD). Everyone living long enough will become eligible for risk-based statin therapy due to age alone.This study sought to personalize ACC/AHA risk-based (...) statin eligibility using noninvasive assessment of subclinical atherosclerosis.In 5,805 BioImage participants without known ASCVD at baseline, those with ≥7.5% 10-year ASCVD risk were down-classified from statin eligible to ineligible if imaging revealed no coronary artery calcium (CAC) or carotid plaque burden (cPB). Intermediate-risk individuals were up-classified from optional to clear statin eligibility if CAC was ≥100 (or equivalent cPB).At a median follow-up of 2.7 years, 91 patients had

2016 EvidenceUpdates

192. Statin Use and Survival After Acute Kidney Injury Full Text available with Trip Pro

Statin Use and Survival After Acute Kidney Injury The incidence of acute kidney injury (AKI) in hospitalized patients is rising, and survivors are at high risk for cardiovascular events and mortality. Effective strategies that improve long-term outcomes of AKI are unknown.A retrospective cohort study was performed between 2008 and 2011. All subjects were followed until 31 March 2013, with a minimum follow-up of 2 years. Participants were adults 18 years of age or older, who developed AKI (...) during a hospitalization and had chronic kidney disease (CKD) following discharge (n = 19,707 mean age 69.9 years, mean postdischarge estimated glomerular filtration rate (eGFR) 43.0 ml/min/1.73 m2). Exposure to statins was examined prior to the index hospitalization as well as within 2 years following hospital discharge. The primary outcome was mortality; secondary outcomes included all-cause re-hospitalization and cardiovascular events.Within 2 years of discharge, only 38.3% of the participants

2016 Kidney international reports

193. Does co-enzyme Q10 reduce statin-related muscle pain?

Does co-enzyme Q10 reduce statin-related muscle pain? Does co-enzyme Q10 reduce statin-related muscle pain? – Morsels of Evidence \t\t\t\r\n\t\t\t \t\t\t\r\n\t\t\t Like this: Like Loading... ","author":{"@type":"Person","name":"Michael Tam"},"image":["https:\/\/evidencebasedmedicine.com.au\/wp-content\/uploads\/2016\/08\/mo-aug2016cover.png"]} Toggle search form Toggle navigation Evidence-based medicine for general practitioners Aug 08 2016 Does co-enzyme Q10 reduce statin-related muscle pain (...) ? By in , , , , , Journal reference: Banach M, Serban C, Sahebkar A, et al. Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials. Mayo Clin Proc 2015 Jan;90(1):24-34. Link: Published: January 2015 Evidence cookie says… The effect of CoQ10 on muscle pain in people on statin therapy is uncertain. The research evidence is of limited quality and inconsistent. The range of best estimates includes no effect. CoQ10 cannot be recommended as a matter of routine supplementation

2016 Morsels of Evidence

194. Statins for age-related macular degeneration. Full Text available with Trip Pro

Statins for age-related macular degeneration. Age-related macular degeneration (AMD) is a progressive, late-onset disorder of the macula affecting central vision. It is the leading cause of blindness in people over 65 years in industrialized countries. Recent epidemiologic, genetic, and pathological evidence has shown that AMD shares a number of risk factors with atherosclerosis, leading to the hypothesis that statins may exert protective effects in AMD.The objective of this review (...) was to examine the effectiveness of statins compared with other treatments, no treatment, or placebo in delaying the onset and progression of AMD.We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Trials Register) (2016, Issue 3), Ovid MEDLINE, Ovid MEDLINE In-Process and Other Non-Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE (January 1946 to March 2016), EMBASE (January 1980 to March 2016), Latin American and Caribbean Health

2016 Cochrane

195. Effect of Targeting Inflammation With Salsalate: The TINSAL-CVD Randomized Clinical Trial on Progression of Coronary Plaque in Overweight and Obese Patients Using Statins. Full Text available with Trip Pro

Effect of Targeting Inflammation With Salsalate: The TINSAL-CVD Randomized Clinical Trial on Progression of Coronary Plaque in Overweight and Obese Patients Using Statins. Inflammation may contribute to pathological associations among obesity, diabetes mellitus, and cardiovascular disease.To determine whether targeting inflammation using salsalate compared with placebo reduces progression of noncalcified coronary artery plaque.In the Targeting Inflammation Using Salsalate in Cardiovascular (...) Disease (TINSAL-CVD) trial participants were randomly assigned between September 23, 2008, and July 5, 2012, to 30 months of salsalate or placebo in addition to standard, guideline-based therapies. Randomization was computerized and centrally allocated, with patients, health care professionals, and researchers masked to treatment assignment. Participants were overweight and obese statin-using patients with established, stable coronary heart disease.Salsalate (3.5 g/d) or placebo orally over 30

2016 JAMA cardiology Controlled trial quality: predicted high

196. Discontinuation and restarting in patients on statin treatment: prospective open cohort study using a primary care database. Full Text available with Trip Pro

Discontinuation and restarting in patients on statin treatment: prospective open cohort study using a primary care database.  To estimate rates of discontinuation and restarting of statins, and to identify patient characteristics associated with either discontinuation or restarting. Prospective open cohort study. 664 general practices contributing to the Clinical Practice Research Datalink in the United Kingdom. Data extracted in October 2014. Incident statin users aged 25-84 years identified (...) between January 2002 and September 2013. Patients with statin prescriptions divided into two groups: primary prevention and secondary prevention (those already diagnosed with cardiovascular disease). Patients with statin prescriptions in the 12 months before study entry were excluded. Discontinuation of statin treatment (first 90 day gap after the estimated end date of a statin prescription), and restarting statin treatment for those who discontinued (defined as any subsequent prescription between

2016 BMJ

197. Impact of statin related media coverage on use of statins: interrupted time series analysis with UK primary care data. Full Text available with Trip Pro

Impact of statin related media coverage on use of statins: interrupted time series analysis with UK primary care data.  To quantify how a period of intense media coverage of controversy over the risk:benefit balance of statins affected their use. Interrupted time series analysis of prospectively collected electronic data from primary care. Clinical Practice Research Datalink (CPRD) in the United Kingdom. Patients newly eligible for or currently taking statins for primary and secondary (...) cardiovascular disease prevention in each month in January 2011-March 2015. Adjusted odds ratios for starting/stopping taking statins after the media coverage (October 2013-March 2014). There was no evidence that the period of high media coverage was associated with changes in statin initiation among patients with a high recorded risk score for cardiovascular disease (primary prevention) or a recent cardiovascular event (secondary prevention) (odds ratio 0.99 (95% confidence interval 0.87 to 1.13; P=0.92

2016 BMJ

198. Statins Use and Risk of Breast Cancer Recurrence and Death: A Systematic Review and Meta-Analysis of Observational Studies. Full Text available with Trip Pro

Statins Use and Risk of Breast Cancer Recurrence and Death: A Systematic Review and Meta-Analysis of Observational Studies. Statins are widely prescribed drugs for lowering cholesterol. Some studies have suggested that statins can prevent breast cancer recurrence and reduce mortality rate. However they are not conclusive. Present systematic review and meta-analysis of published cohort studies was conducted to determine the effects of statins intake and risk of breast cancer recurrence (...) and mortality rate.Online databases (PubMed, Embase, Scopus, EBSCO and Cochrane Collaboration) were searched through October 2014. Pooled relative risks and 95 % confidence intervals were calculated with random-effects.A total of 8 cohort studies (4 for recurrence 2 for mortality and 2 for both) involving 124669 participants with breast cancer were eligible. Our results suggest a significant reduction in recurrence (OR= 0.79. I2= 38%) and death (OR = 0.84, I2 = 8.58 %) among statin users.Our meta-analysis

2016 Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Société canadienne des sciences pharmaceutiques

199. PCSK9 Inhibitors for Statin Intolerance? Full Text available with Trip Pro

PCSK9 Inhibitors for Statin Intolerance? 27039138 2016 05 02 2018 12 02 1538-3598 315 15 2016 Apr 19 JAMA JAMA PCSK9 Inhibitors for Statin Intolerance? 1571-2 10.1001/jama.2016.3670 Waters David D DD Division of Cardiology, San Francisco General Hospital, San Francisco, California2Department of Medicine, University of California-San Francisco. Hsue Priscilla Y PY Division of Cardiology, San Francisco General Hospital, San Francisco, California2Department of Medicine, University of California

2016 JAMA

200. Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial. Full Text available with Trip Pro

Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial. Muscle-related statin intolerance is reported by 5% to 20% of patients.To identify patients with muscle symptoms confirmed by statin rechallenge and compare lipid-lowering efficacy for 2 nonstatin therapies, ezetimibe and evolocumab.Two-stage randomized clinical trial including 511 adult patients with uncontrolled low-density lipoprotein cholesterol (...) (LDL-C) levels and history of intolerance to 2 or more statins enrolled in 2013 and 2014 globally. Phase A used a 24-week crossover procedure with atorvastatin or placebo to identify patients having symptoms only with atorvastatin but not placebo. In phase B, after a 2-week washout, patients were randomized to ezetimibe or evolocumab for 24 weeks.Phase A: atorvastatin (20 mg) vs placebo. Phase B: randomization 2:1 to subcutaneous evolocumab (420 mg monthly) or oral ezetimibe (10 mg daily).Coprimary

2016 JAMA Controlled trial quality: predicted high